Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA: 14 sponsored US clinical trials, none currently recruiting.
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 3 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
NCT04948554
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
NCT04811092
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
NCT04896008
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
NCT04576988
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
NCT03943290
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
NCT03738150
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT03496207
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
NCT03124459
Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02927080
Phase 1 Study of ACE-083 in Healthy Subjects
NCT02257489
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT02024087
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT01727336
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT01458392
Study of ACE-536 in Healthy Postmenopausal Women
NCT01432717
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 3 | 3 |
How the Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA early-phase archive is shaped
14 indexed studies, none listed as recruiting (0% open); 8 completed (57%).
Phase mix: 3 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Therapeutic area indexing for this sponsor is limited in the public registry.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Aerin Medical · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA page
14 registered trials is a research-attention snapshot, not an endorsement of Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA or any single study.
- None of Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA pipeline card: 14 registered trials from official public datasets.Report a data error.